The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ the New Drug Application ...

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will ...

The new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025 ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Soleno Therapeutics. Looking at options history ...

Following the U.S. Food and Drug Administration extending the review period for the company's New Drug Application (NDA) for ...

Soleno Therapeutics ( NASDAQ: SLNO) fell about 17% in premarket trading after the U.S. FDA extended the review period for its ...

("Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...

Soleno Therapeutics ( (SLNO) ) has released its Q3 earnings. Here is a breakdown of the information Soleno Therapeutics presented to its ...